SPONSOR

AstraZeneca

Total Trials

Recruiting

Phases

Phase 1, Phase 3, Phase 2, Phase 1, Phase 2, Phase 4

Conditions studied: Rheumatoid Arthritis Systemic Lupus Erythematosus Chronic Lymphocytic Leukemia Gastric Cancer Gastroesophageal Junction Cancer Lung Cancer Healthy Participants Untreated Follicular Lymphoma Transthyretin Amyloidosis Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance

AstraZeneca is a British-Swedish multinational biopharmaceutical company with one of the industry's most active clinical pipelines in oncology, cardiovascular-renal-metabolic disease, respiratory and immunology, and rare diseases. Founded in 1999 through the merger of Astra AB and Zeneca Group, AstraZeneca today invests approximately $9–10 billion annually in R&D. Their trial portfolio is notable for several landmark programs including the DAPA-HF and DAPA-CKD trials (dapagliflozin), the ADAURA and LAURA trials (osimertinib for lung cancer), and the AstraZeneca-Oxford COVID-19 vaccine development.

AstraZeneca's oncology unit — operating as AstraZeneca Oncology — maintains deep expertise in targeted therapy for EGFR-mutated non-small cell lung cancer, HER2-targeted therapies (trastuzumab deruxtecan, developed with Daiichi Sankyo), PARP inhibitors for ovarian and breast cancer (olaparib), and immuno-oncology through the PD-L1 inhibitor durvalumab. The cardiovascular and metabolic portfolio includes one of the most extensive SGLT2 inhibitor trial programs ever conducted, spanning heart failure, chronic kidney disease, and type 2 diabetes across thousands of participants in dozens of countries.

AstraZeneca's clinical trials are conducted at leading academic and community research centers worldwide. The company has made public commitments to diversity in clinical research and has implemented specific protocols to increase enrollment from historically underrepresented groups. AstraZeneca participates in pre-competitive partnerships through organizations such as the Innovative Medicines Initiative (IMI) and TransCelerate BioPharma.

Frequently Asked Questions — AstraZeneca

What is AstraZeneca best known for in clinical research?

AstraZeneca is best known clinically for three major areas: (1) lung cancer — their EGFR inhibitor osimertinib (Tagrisso) demonstrated unprecedented survival improvements in adjuvant NSCLC and is the subject of ongoing trials in earlier disease stages and combination settings; (2) heart failure and kidney disease — dapagliflozin (Farxiga) has been shown in Phase 3 trials to significantly reduce hospitalization and mortality across both heart failure subtypes and in CKD independent of diabetes; and (3) PD-L1 inhibition — durvalumab (Imfinzi) has received approvals in multiple cancer indications and is under investigation in dozens of additional combinations.

Does AstraZeneca run trials outside of cancer?

Yes. While oncology represents the largest share of AstraZeneca's current trial portfolio, the company has equally robust programs in cardiovascular, renal, and metabolic disease (CVRM), respiratory and immunology, and rare diseases. Their CVRM trials include investigations of SGLT2 inhibitors, GLP-1/GIP agonists (in collaboration with partners), and novel mechanisms in heart failure. The respiratory portfolio covers severe asthma (benralizumab, tezepelumab), COPD, and interstitial lung disease. Rare disease trials focus on conditions with high unmet medical need including complement-mediated diseases and severe respiratory disorders.

How does AstraZeneca approach diversity and inclusion in clinical trials?

AstraZeneca has a published global diversity and inclusion framework for clinical trials that sets targets for enrollment of women, patients from racial and ethnic minority groups, and older adults across all Phase 2 and Phase 3 studies. The company works with community organizations and patient advocacy groups to identify and address barriers to participation — including transportation, language, and lack of awareness — particularly for oncology and rare disease trials where underrepresentation has historically been greatest. These commitments are reported annually in AstraZeneca's Global Sustainability Report.

AstraZeneca

Frequently Asked Questions — AstraZeneca

Clinical Trials by AstraZeneca

Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants

Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study

A Study to Investigate the Pharmacokinetics of Different Formulations and Safety of AZD5004 in Healthy Participants Aged 18 to 55 Years

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

The Eplontersen Pregnancy and Lactation Outcomes Study

UmbREALung - A Retrospective and Prospective, Observational, Real World Multi-cohort Study of Patients With Non-small Cell Lung Cancer (NSCLC) Initiating Approved Drugs Developed by AZ or as Part of an AZ Alliance

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

Anifrolumab Malignancy and Serious Infections Study

The Anifrolumab PRIM Program

A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

OPTIMISE-CKD Study_Dapagliflozin Effectiveness in CKD

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment

A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases

Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease

A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

Tezspire Cardiac Events PASS

A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.

Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody

Durvalumab Consolidation After Chemoradiation Therapy for Limited Stage SCLC in China

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

The Burden of Atypical Hemolytic Uremic Syndrome and The Clinical Characteristics of Patients in Egyptian Hospitals A Multicenter, Observational, Retrospective Cohort Study in Egypt

A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)